TransMedics Group, Inc. (TMDX)

$47

+0.06 (+0.13%)
Rating:
Recommendation:
-
Symbol TMDX
Price $47
Beta 1.633
Volume Avg. 0.35M
Market Cap 1.496B
Shares () -
52 Week Range 10.0-49.27
1y Target Est -
DCF Unlevered TMDX DCF ->
DCF Levered TMDX LDCF ->
ROE -74.20% Strong Sell
ROA -40.68% Strong Sell
Operating Margin -
Debt / Equity 130.34% Buy
P/E -
P/B 25.83 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest TMDX news


Dr. Waleed H. Hassanein
Healthcare
Medical Devices
NASDAQ Global Market

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.